Introduction Brigatinib and alectinib are second-generation anaplastic lymphoma kinase inhibitors (ALKis) and both are used as first-line standard-of-care for advanced ALK-rearranged (ALK+) non-small-cell lung cancer (NSCLC) based on the results of two randomized Phase 3 trials.1 The ALTA-1L trial compared brigatinib vs crizotinib as first-line therapy for ALK+ NSCLC; brigatinib significantly prolonged median progression-free survival (mPFS), the primary endpoint, from 11.1 to 24 months,...